ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 162 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2018. The put-call ratio across all filers is 2.52 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $266,000 | -22.0% | 7,260 | -0.9% | 0.01% | -28.6% |
| Q2 2019 | $341,000 | -8.1% | 7,326 | -20.7% | 0.01% | -12.5% |
| Q1 2019 | $371,000 | -10.0% | 9,240 | +3.2% | 0.01% | -20.0% |
| Q4 2018 | $412,000 | -13.8% | 8,954 | -16.9% | 0.01% | +11.1% |
| Q3 2018 | $478,000 | +753.6% | 10,780 | +653.8% | 0.01% | +800.0% |
| Q2 2018 | $56,000 | -95.4% | 1,430 | -91.7% | 0.00% | -92.3% |
| Q1 2018 | $1,226,000 | +452.3% | 17,248 | +412.4% | 0.01% | +160.0% |
| Q4 2017 | $222,000 | -23.7% | 3,366 | -42.0% | 0.01% | -28.6% |
| Q3 2017 | $291,000 | -3.3% | 5,808 | -10.8% | 0.01% | 0.0% |
| Q2 2017 | $301,000 | -2.3% | 6,512 | -25.3% | 0.01% | 0.0% |
| Q1 2017 | $308,000 | +182.6% | 8,712 | 0.0% | 0.01% | +133.3% |
| Q4 2016 | $109,000 | – | 8,712 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
| Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
| Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
| Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
| SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
| Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
| CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
| Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |